HUE046606T2 - Neratinib maleát tabletta formái - Google Patents

Neratinib maleát tabletta formái

Info

Publication number
HUE046606T2
HUE046606T2 HUE10779339A HUE10779339A HUE046606T2 HU E046606 T2 HUE046606 T2 HU E046606T2 HU E10779339 A HUE10779339 A HU E10779339A HU E10779339 A HUE10779339 A HU E10779339A HU E046606 T2 HUE046606 T2 HU E046606T2
Authority
HU
Hungary
Prior art keywords
tablet formulations
neratinib maleate
neratinib
maleate
formulations
Prior art date
Application number
HUE10779339A
Other languages
English (en)
Inventor
Muhammad Ashraf
Krishnendu Ghosh
Chimanlall Goolcharran
Mainuddin Mahmud
Arwinder Singh Nagi
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE046606(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of HUE046606T2 publication Critical patent/HUE046606T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE10779339A 2009-11-09 2010-11-02 Neratinib maleát tabletta formái HUE046606T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25940309P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
HUE046606T2 true HUE046606T2 (hu) 2020-03-30

Family

ID=43478191

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10779339A HUE046606T2 (hu) 2009-11-09 2010-11-02 Neratinib maleát tabletta formái

Country Status (21)

Country Link
US (2) US8518446B2 (hu)
EP (3) EP2498756B2 (hu)
JP (3) JP5835883B2 (hu)
CN (2) CN102724970B (hu)
AR (2) AR078952A1 (hu)
AU (1) AU2010316683B2 (hu)
CA (1) CA2780428C (hu)
CY (1) CY1122330T1 (hu)
DK (1) DK2498756T4 (hu)
ES (1) ES2757882T5 (hu)
FI (1) FI2498756T4 (hu)
HR (1) HRP20192026T4 (hu)
HU (1) HUE046606T2 (hu)
LT (1) LT2498756T (hu)
NZ (1) NZ599763A (hu)
PL (1) PL2498756T5 (hu)
PT (1) PT2498756T (hu)
RS (1) RS59599B2 (hu)
SI (1) SI2498756T2 (hu)
TW (1) TWI466690B (hu)
WO (1) WO2011055303A1 (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20130088908A (ko) 2008-06-17 2013-08-08 와이어쓰 엘엘씨 Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
LT2498756T (lt) * 2009-11-09 2019-12-10 Wyeth Llc Neratinibo maleato tablečių sudėtis
CN107441058A (zh) 2009-11-09 2017-12-08 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
FI3738434T3 (fi) 2011-12-28 2023-11-20 Global Blood Therapeutics Inc Välituotteita substituoitujen bentsaldehydiyhdisteiden saamiseksi ja menetelmiä niiden käyttöön kudosten hapetuksen lisäämiseksi
CA2902711C (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
CA2903220C (en) 2013-03-15 2023-01-24 Qing Xu Aldehyde compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2903022C (en) 2013-03-15 2021-11-09 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9818967B2 (en) * 2013-06-28 2017-11-14 Universal Display Corporation Barrier covered microlens films
CN104337782A (zh) * 2013-08-02 2015-02-11 山东新时代药业有限公司 一种甲磺酸伊马替尼片剂
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015112850A2 (en) * 2014-01-23 2015-07-30 Wenle Xia Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
PE20201444A1 (es) 2014-02-07 2020-12-10 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido
CA2939345C (en) 2014-02-17 2022-05-31 Children's National Medical Center Method and system for providing recommendation for optimal execution of surgical procedures
PE20170523A1 (es) * 2014-07-25 2017-05-17 Novartis Ag Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida
US10016471B2 (en) 2015-06-29 2018-07-10 Phloronol, Inc. Solid pharmaceutical compositions of brown algae
WO2017096230A1 (en) 2015-12-04 2017-06-08 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN106831710A (zh) * 2015-12-07 2017-06-13 常州爱诺新睿医药技术有限公司 一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
CN106913529B (zh) * 2015-12-24 2020-12-04 江苏恒瑞医药股份有限公司 一种来那替尼或其可药用盐药物组合物的制备方法
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
JP2019529534A (ja) * 2016-09-07 2019-10-17 セルジーン コーポレイション 錠剤組成物
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP7525264B2 (ja) * 2017-04-28 2024-07-30 リベルタス バイオ,インコーポレイティド アトピー性皮膚炎の治療及び原薬の安定性を向上するための製剤、方法、キット、及び剤形
KR20200078561A (ko) * 2017-10-24 2020-07-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 퀴놀린 유도체를 함유하는 약학 조성물
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
IL297776A (en) * 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
US20220378788A1 (en) * 2020-04-30 2022-12-01 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
MX2022016341A (es) * 2020-06-19 2023-01-24 Acerta Pharma Bv Formas farmaceuticas de maleato de acalabrutinib.
TW202345857A (zh) * 2022-03-08 2023-12-01 美商昂科斯克塞爾醫療有限責任公司 他波司他之穩定調配物
WO2024187321A1 (zh) * 2023-03-10 2024-09-19 甫康(上海)健康科技有限责任公司 含有egfr抑制剂的药物组合物及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
AR046544A1 (es) * 2003-10-15 2005-12-14 Wyeth Corp Administracion oral de acido [2- (8,9 - dioxo - 2,6 - diazabiciclo [5.2.0] non -1 (7) - en - 2 - il ) alquil] fosfonico yderivados
JP2008515984A (ja) * 2004-10-13 2008-05-15 ワイス Pi3k阻害剤としての17−ヒドロキシワートマニンの類似体
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
CA2603806C (en) * 2005-04-28 2013-03-19 Wyeth Micronized tanaproget, compositions, and methods of preparing the same
EP1948180B1 (en) * 2005-11-11 2013-03-13 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
JP2007169273A (ja) * 2005-11-28 2007-07-05 Takeda Chem Ind Ltd 杵付着を改善した医薬製剤
JP2007211005A (ja) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd 固形製剤用組成物および固形製剤
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
AR064875A1 (es) * 2007-01-12 2009-04-29 Wyeth Corp Composiciones de tableta en tableta
ES2639854T3 (es) * 2007-02-01 2017-10-30 Takeda Pharmaceutical Company Limited Preparación de comprimidos sin causar problemas de fabricación de comprimidos
JP2009089982A (ja) * 2007-10-11 2009-04-30 Ohara Yakuhin Kogyo Kk 打錠用造粒物の造粒方法
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
CA2766067A1 (en) * 2009-07-02 2011-01-06 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
LT2498756T (lt) * 2009-11-09 2019-12-10 Wyeth Llc Neratinibo maleato tablečių sudėtis

Also Published As

Publication number Publication date
CN102724970A (zh) 2012-10-10
AR114143A2 (es) 2020-07-29
SI2498756T1 (sl) 2020-01-31
CN102724970B (zh) 2014-06-25
US8790708B2 (en) 2014-07-29
FI2498756T4 (fi) 2023-03-22
JP2011098964A (ja) 2011-05-19
CN103893140A (zh) 2014-07-02
SI2498756T2 (sl) 2023-04-28
AR078952A1 (es) 2011-12-14
AU2010316683B2 (en) 2015-10-08
JP5835883B2 (ja) 2015-12-24
US8518446B2 (en) 2013-08-27
CA2780428C (en) 2018-02-13
EP3566697B1 (en) 2024-09-11
JP2017075192A (ja) 2017-04-20
DK2498756T3 (da) 2019-11-25
ES2757882T3 (es) 2020-04-30
EP2498756A1 (en) 2012-09-19
EP3566697A1 (en) 2019-11-13
CY1122330T1 (el) 2021-01-27
HRP20192026T4 (hr) 2023-03-31
TW201138774A (en) 2011-11-16
AU2010316683A1 (en) 2012-05-24
RS59599B2 (sr) 2023-03-31
DK2498756T4 (da) 2023-03-20
PL2498756T5 (pl) 2023-04-17
EP2498756B2 (en) 2023-02-15
WO2011055303A1 (en) 2011-05-12
CN103893140B (zh) 2016-06-01
ES2757882T5 (es) 2023-05-10
HRP20192026T1 (hr) 2020-02-07
LT2498756T (lt) 2019-12-10
PL2498756T3 (pl) 2020-03-31
TWI466690B (zh) 2015-01-01
CA2780428A1 (en) 2011-05-12
EP4066821A1 (en) 2022-10-05
US20110111018A1 (en) 2011-05-12
EP2498756B1 (en) 2019-09-04
NZ599763A (en) 2014-06-27
PT2498756T (pt) 2019-11-26
RS59599B1 (sr) 2020-01-31
JP2015091882A (ja) 2015-05-14
US20140004184A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
LT2498756T (lt) Neratinibo maleato tablečių sudėtis
HUS2000009I1 (hu) Kétrétegû tabletta készítmények
HRP20181755T1 (hr) Formulacije tableta s trenutnim oslobađanjem
PT3061445T (pt) Formulações farmacêuticas altamente concentradas
HK1169960A1 (en) Pharmaceutical formulation
IL215872A (en) Indomethacin preparation
HK1198287A1 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives 2--1-
HK1209649A1 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives 2--1-
HK1201759A1 (en) 4-methylpyrazole formulations 4-
EP2473168A4 (en) PHARMACEUTICAL FORMULATIONS FOR INDIBULIN